Press Release – New York, NY – December 2, 2025 – Sichenzia Ross Ference Carmel LLP announced that it represented FibroBiologics, Inc. (Nasdaq: FBLG), a clinical-stage biotechnology company with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, in its recently closed $4 million registered direct offering (priced at-the-market under Nasdaq rules) of shares of common stock and pre-funded warrants and its concurrent private placement of unregistered warrants to purchase common stock. The unregistered warrants will be exercisable beginning on the effective date of, and subject to, approval by the company’s stockholders of the issuance of the shares of common stock upon exercise of the unregistered warrants. The securities were sold to an existing shareholder, and the purchase price was paid with sovereign-issued .9999 fine gold coins valued at the spot price of gold at the time of signing of the purchase agreement. FBLG intends to liquidate the gold into United States dollars in the near term.
The SRFC team was led by partners Gregory Sichenzia and Barrett DiPaolo, with associates Karina Maas, Lony Leung and Mohit Agrawal.